Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Masitinib - AB Science

Drug Profile

Masitinib - AB Science

Alternative Names: AB 07105; AB-1010; Alsitek; Masican; Masipro; Masitinib mesilate; Masitinib mesylate; Masiviera

Latest Information Update: 10 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AB Science
  • Class Anti-inflammatories; Antiasthmatics; Antidementias; Antineoplastics; Antirheumatics; Benzamides; Nootropics; Piperazines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Colony stimulating factor inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors; Macrophage colony-stimulating factor receptor modulators; Mast cell inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-fyn modulators; Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mastocytosis; Amyotrophic lateral sclerosis; Gastric cancer; Gastrointestinal stromal tumours; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Amyotrophic lateral sclerosis; Mastocytosis
  • Phase III Alzheimer's disease; Asthma; Colorectal cancer; Gastrointestinal stromal tumours; Multiple myeloma; Multiple sclerosis; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer
  • Phase II/III Crohn's disease; Ovarian cancer
  • Phase II Breast cancer; Chronic obstructive pulmonary disease; Head and neck cancer; Non-small cell lung cancer; Parkinson's disease
  • Phase I/II Gastric cancer; Glioblastoma; Liver cancer; Oesophageal cancer
  • No development reported Psoriasis; Stroke
  • Discontinued Malignant melanoma; Mood disorders; Progressive supranuclear palsy; Rheumatoid arthritis

Most Recent Events

  • 07 Nov 2019 AB Science has patent protection for masitinib in the US, covering its use for the treatment of asthma
  • 07 Nov 2019 Efficacy and adverse events data from a phase III trial in Asthma released by AB Science
  • 04 Nov 2019 AB Science announces intention to file marketing authorization for Systemic mastocytosis in 2022
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top